Gilead Sciences (GILD) FY2025 10-K Annual Report
Gilead Sciences (GILD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Gilead Sciences FY2025 10-K Analysis
Business Overview
- • Biopharmaceutical company focused on HIV, viral hepatitis, COVID-19, and oncology; commercial portfolio of 25+ therapies distributed across 35+ countries via wholesale channel (~90% of U.S. sales through 3 wholesalers)
- • Yeztugo/Yeytuo (lenacapavir) approved as first and only twice-yearly HIV PrEP option in both U.S. and EU; multiple BLA filings pending for anitocabtagene autoleucel (multiple myeloma) and expanded Trodelvy indications in TNBC first-line and NSCLC
- • Pipeline expansion into immuno-oncology via Arcus collaboration: domvanalimab + zimberelimab (anti-TIGIT + anti-PD-1) in Phase 3 for first-line metastatic NSCLC — new competitive thrust beyond CAR-T and ADC
- • ~17,000 employees as of December 31, 2025
- • Biktarvy patent litigation settled with Lupin, Cipla, and Laurus in October 2025; no generic entry expected before April 1, 2036 in the U.S.
Management Discussion & Analysis
- • Revenue $29.4B in 2025, up 2% YoY; HIV +6% to $20.8B best performer; Veklury -49% to $911M worst performer
- • Product gross margin 78.4% vs 78.2% (+29 bps); SG&A down 5% to $5.8B; effective tax rate 13.1% vs 30.5%
- • Net income $8.5B vs $480M YoY; driven by absence of $3.8B CymaBay IPR&D charge and lower IPR&D impairments ($590M vs $4.2B)
- • Operating cash flow $10.0B; dividends $4.0B; buybacks $1.9B; debt repaid $1.8B; cash/securities $10.6B at year-end
- • 2026 outlook: HIV growth expected; offset by Veklury decline, Cell Therapy competitive headwinds, and U.S. policy-related impacts
Risk Factors
- • IRA + MFN pricing: Biktarvy selected for Medicare price negotiation effective 2028; Gilead signed Dec 2025 agreement implementing MFN Medicaid prices and pausing Section 232 tariffs for 3 years
- • Pharmaceutical tariff exposure: U.S. administration announced plans for up to 100% tariffs on imported branded/patented pharmaceuticals; Gilead sources significant raw materials and intermediates from outside U.S.
- • CAR T-cell supply chain: relies on third-party apheresis centers, shippers, and single-source tocilizumab/corticosteroid suppliers; disruption risks product loss and regulatory action
- • BIOSECURE Act operational risk: prohibits U.S. agency contracts with certain foreign biotech entities used by Gilead in clinical trials and commercial manufacturing, threatening supply and trial timelines
- • Revenue concentration: ~90% of U.S. gross product sales flow through just three wholesalers — Cardinal Health, Cencora, and McKesson
Gilead Sciences FY2025 Key Financial MetricsXBRL
Revenue
$29.4B
▲ +2.4% YoY
Net Income
$8.5B
▲ +1672.9% YoY
Operating Margin
34.0%
▲ +2826bp YoY
Net Margin
28.9%
▲ +2723bp YoY
ROE
37.5%
▲ +3500bp YoY
Total Assets
$59.0B
▲ +0.0% YoY
EPS (Diluted)
$6.78
▲ +1684.2% YoY
Operating Cash Flow
$10.0B
▼ -7.5% YoY
Source: XBRL data from Gilead Sciences FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Annual Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.